Reiss, Peter

A Randomized, Double-blind Trial Comparing Combinations of Nevirapine, Didanosine, and Zidovudine for HIV-Infected Patients: The INCAS Trial

Montaner, J. S. G., Reiss, P., Cooper, D., Vella, S., Harris, M., Conway, B., Wainberg, M. A., Smith, D., Robinson, P., Hall, D., et al. (1998) · JAMA

HIV/AIDS drug development and treatmentHIV/AIDS Research and Interventions

Cited by 756

Predicting the risk of cardiovascular disease in HIV-infected patients: the Data collection on Adverse Effects of Anti-HIV Drugs Study

Friis-Møller, N., Thiébaut, R., Reiss, P., Weber, R., D'Arminio Monforte, A., De Wit, S., El-Sadr, W., Fontas, E., Worm, S., Kirk, O., et al. (2010) · European Journal of Cardiovascular Prevention & Rehabilitation

HIV-related health complications and treatmentsLipoproteins and Cardiovascular Health

Cited by 384

Smoking and life expectancy among HIV-infected individuals on antiretroviral therapy in Europe and North America

Helleberg, M., May, M. T., Ingle, S. M., Dabis, F., Reiss, P., Fätkenheuer, G., Costagliola, D., d’Arminio, A., Cavassini, M., Smith, C., et al. (2015) · AIDS

HIV-related health complications and treatmentsSmoking Behavior and Cessation

Cited by 268

European AIDS Clinical Society (EACS) guidelines on the prevention and management of metabolic diseases in HIV*

Lundgren, J., Battegay, M., Behrens, G., De Wit, S., Guaraldi, G., Katlama, C., Martinez, E., Nair, D., Powderly, W., Reiss, P., et al. (2008) · HIV Medicine

HIV-related health complications and treatmentsDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 210

Pharmacokinetics and pharmacodynamics of combined use of lopinavir/ritonavir and rosuvastatin in HIV-infected patients

Van Der Lee, M., Sankatsing, R., Schippers, E., Vogel, M., Fätkenheuer, G., Van Der Ven, A., Kroon, F., Rockstroh, J., Wyen, C., Bäumer, A., et al. (2007) · Antiviral Therapy

Lipoproteins and Cardiovascular HealthHIV/AIDS drug development and treatment

Cited by 78

Bone mineral density and inflammatory and bone biomarkers after darunavir–ritonavir combined with either raltegravir or tenofovir–emtricitabine in antiretroviral-naive adults with HIV-1: A substudy of the NEAT001/ANRS143 randomised trial

Bernardino, J. I., Mocroft, A., Mallon, P. W., Wallet, C., Gerstoft, J., Russell, C., Reiss, P., Katlama, C., De Wit, S., Richert, L., et al. (2015) · The Lancet HIV

HIV-related health complications and treatmentsHIV/AIDS drug development and treatment

Cited by 76